Cost-effectiveness analysis of thiopurine methyltransferase (TPMT) screening and metabolite monitoring (MM) in the management of azathioprine (AZA)-treated Crohn's disease (CD) patients

Dubinsky, Marla; Reyes, Eileen; Ofman, Joshua; Chiou, Chiun-Fang; Wade, Sally; Sandborn, William J
September 2003
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS233
Academic Journal
An abstract of the article "Cost-effectiveness analysis of thiopurine methyltransferase (TPMT) screening and metabolite monitoring (MM) in the management of azathioprine (AZA)-treated Crohn's disease (CD) patients," by Marla Dubinsky and colleagues is presented.


Related Articles

  • Cost-Effectiveness of Budesonide Controlled Ileal Release (CIR) Capsules as Maintenance Therapy versus No Maintenance Therapy for Ileocaecal Crohn's Disease in Sweden. Noble, I.; Brown, R.; Danielsson Å.; Ericsson, K.; Florén, C-H.; Hertzman, P.; Löfberg, R. // Clinical Drug Investigation;1998, Vol. 15 Issue 2, p123 

    A decision-analytic model was designed to estimate the associated costs and outcomes of maintenance therapy for Crohn's disease with budesonide controlled ileal release (CIR) capsules (Entocort capsules, Astra Draco, Lund, Sweden) versus no maintenance therapy. A third-party payer perspective...

  • Scheduled infliximab maintenance worthy for Crohn's disease in UK.  // PharmacoEconomics & Outcomes News;8/9/2008, Issue 559, p11 

    The article discusses research being done on infliximab. It references a study by J. Lindsay et al, published in the July 1, 2008 issue of "Alimentary Pharmacology and Therapeutics." The analysis revealed the cost effectiveness of scheduled infliximab maintenance therapy in patients with Crohn's...

  • Which biological treatment for Crohn's disease in the US?  // PharmacoEconomics & Outcomes News;5/12/2012, Issue 653, p9 

    The article discusses research on the cost effectiveness of biologic treatments for moderate-to-severe Crohn's disease, referencing a study by D. H. Tang and colleagues published on the April 23, 2012 issue of "Pharmacotherapy."chr

  • Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease. Yu, Andrew P.; Johnson, Scott; Si-Tien Wang; Atanasov, Pavel; Tang, Jackson; Wu, Eric; Jingdong Chao; Mulani, Parvez M. // PharmacoEconomics;2009, Vol. 27 Issue 7, p609 

    Objective: To determine and compare the cost utilities of the tumour necrosis factor (TNF) antagonists adalimumab and infliximab as maintenance therapies for patients in the US with moderately to severely active Crohn's disease. Methods: Maintenance regimens of adalimumab (40mg every other week)...

  • Certolizumab pegol wins as third-line therapy for Crohn's disease.  // PharmacoEconomics & Outcomes News;10/15/2011, Issue 639, p8 

    The article discusses the results of a study which showed that using certolizumab, a tumor necrosis factor (TNF)-antagonist, is cost effective compared with switching to natalizumab, an integrin-alpha-4beta1 antagonist, for patients with moderate-to-severe Crohn's disease.

  • Crohn's disease news from DDW.  // PharmacoEconomics & Outcomes News;5/28/2011, Issue 629, p8 

    The article discusses studies on Crohn's disease presented at the Digestive Disease Week meeting held in Chicago, Illinois in May 2011. One of the studies examined the cost effectiveness of azathioprine for the treatment of patients with moderate-to-severe Crohn's disease, compared with...

  • A Cost-Effectiveness Analysis of Alternative Disease Management Strategies in Patients with Crohn's Disease Treated with Azathioprine or 6-Mercaptopurine. Dubinsky, Marla C.; Reyes, Eileen; Ofman, Joshua; Chiun-Fang Chiou; Wade, Sally; Sandborn, William J. // American Journal of Gastroenterology;Oct2005, Vol. 100 Issue 10, p2239 

    BACKGROUND: Azathioprine (AZA) is effective for the maintenance of a steroid free remission in Crohn's disease (CD). Thiopurine methyltransferase (TPMT) is important for the metabolism of AZA and influences the production of active AZA metabolites. AZA dose selection based on pharmacogenetic...

  • Colectomy with Permanent End Ileostomy Is More Cost-Effective than Ileal Pouch-Anal Anastomosis for Crohn's Colitis. Taleban, Sasha; Oijen, Martijn; Vasiliauskas, Eric; Fleshner, Phillip; Shen, Bo; Ippoliti, Andrew; Targan, Stephan; Melmed, Gil; Van Oijen, Martijn G H; Vasiliauskas, Eric A; Fleshner, Phillip R; Ippoliti, Andrew F; Targan, Stephan R; Melmed, Gil Y // Digestive Diseases & Sciences;Feb2016, Vol. 61 Issue 2, p550 

    Background: Much of the economic burden of Crohn's disease (CD) is related to surgery. Twenty percent of patients with CD have isolated colonic disease. While permanent end ileostomy (EI) is generally the procedure of choice for patients with refractory CD colitis, single-center...

  • Infliximab Dosing for Crohn's Disease: Too Much of a Good Thing? Kaddis, Atheer A. // American Health & Drug Benefits;Apr2014, Vol. 7 Issue 2, p93 

    The author discusses dosing of infliximab for Crohn's disease, making reference to a study by Joseph Tkacz and colleagues published within the journal. He addresses the issue on findings of the study that prevalence of dose escalation of 17 percent of patients with Crohn's disease within one...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics